These results indicate that the combination of PTC596 and S63845 or trametinib may be both effective and specific treatments to target adverse risk AML, especially with elevated CD34 positivity, thus providing the rationale for initiating clinical studies evaluating these treatment combinations. Here, CD34 is linked to acute myeloid leukemia.